News provided by GNC Apr 29, 2024, 08:00 ET Global leader in health and wellness redesigns store to assist GLP-1 users on their journey to better health with a dedicated companion product section and specialized employee training PITTSBURGH, April 29, 2024 /PRNewswire/ -- GNC, the global leader in health and wellness, today announced its unprecedented initiative to support individuals using GLP-1 agonists
Santos LF, Silva AS, Mano JF
Multiple sclerosis and related disorders, 27, 52-60.
doi: 10.1136/gut.22.9.763 44 ZamanSASarbiniSR
Several GLP-1RAs, including semaglutide, have been shown to offer cardiovascular outcome benefit in people with T2D 33,34,35
Jaka Vukojevi, Borna Vrdoljak, Dominik Malekinui, Marko Siroglavi, Marija Milavi, Kolenc, D., Alenka Boban Blagai, Lovorka Batelja, Domagoj Drmi, Sven Seiverth, & Predrag Sikiri